Document is current
Any future updates will be listed below
-
Authors
Coskery, Shelley
Erdler, Marcus
Frey, Margaret R.
Lopez, Michael A.
-
Funding
Funding for this research was provided by:
Genentech Foundation
- License Information
-
More Information
Article History
Received: 13 December 2024
Accepted: 5 March 2025
First Online: 27 March 2025
Declarations
:
: Michael A. Lopez reports involvement in consulting and/or clinical trials for Sarepta, Octapharma, and Pfizer. Shelley Coskery, Marcus Erdler, and Margaret R. Frey have no conflicts of interest to declare.
: This study was performed in line with the principles of the Declaration of Helsinki. Approval for the cases from the Memorial Healthcare and University of Alabama were granted by the Western-Copernicus Group Institutional Review Board (2024-0786), an organization that is responsible for protecting the rights and well-being of patients who take part in research studies. The requirement for ethical approval was waived from the Clinic Donaustadt in Vienna, Austria. Patients signed informed consent regarding publishing their data. Data were collected only after the appropriate approvals and waivers had been received.
